Brookfield Asset Management .(US:BAM) newsfilecorp.comยท2024-05-28 11:05Core Insights - Kraig Biocraft Laboratories, Inc. has announced significant advancements in the commercialization of its BAM-1 recombinant spider silk production hybrids, which were first introduced in February 2024 [1][2] - The BAM-1 hybrid system is designed to enhance the production capacity of the company's spider silk technologies, specifically integrating these technologies into production-ready silkworm strains [2][3] - The BAM-1 production platform is characterized as the most robust and scalable system for commercial production of recombinant spider silk, particularly Dragon SilkTM, which combines the properties of spider silk with traditional silk production methods [2][3] Company Developments - The BAM-1 hybrids have demonstrated success in scaling and reliability for Dragon Silk manufacturing, positioning the company ahead of its production schedule for 2024 [3] - The company plans to provide further details on production expansion in the coming weeks, indicating a proactive approach to commercialization [3] Industry Impact - Kraig Labs is recognized as a leading developer of genetically engineered spider silk-based fiber technologies, with implications for the global textile industry [4] - The advancements in spider silk technology are expected to have significant impacts on various applications within the textile sector, enhancing material properties and production efficiency [4]